RBC Capital analysts provided their outlook on Aramark (NYSE:ARMK) ahead of the upcoming Q1 results and raised their price target to $48 from $45.

The analysts expect a modest upside to Q1/23, given the further improvement in RBC's proprietary GOAT Index while encouraging office occupancy data bodes well for continued B&I recovery. Moreover, revenues are recession-resilient, and the analysts expect sustained momentum in new business wins in key verticals such as higher education, K-12, healthcare, and international.

The analysts estimate Q1 revenue of $4.555 billion, modestly above the Street estimate of $4.527 billion, and EPS of $0.42, below the Street estimate of $0.44.